Immunogenicity of Salmonella typhi Ty21a vaccine for young children.
An attenuated Salmonella typhi Ty21a vaccine was administered to 18 infants and toddlers (less than or equal to 24 months old) to determine its safety and immunogenicity. The vaccination (10(9) CFU per dose, three doses) was well tolerated. However, after the vaccination there was no evidence of a humoral or cellular immune response to S. typhi. The vaccine used was known to be immunogenic for older children and adults. The results support the view that the immunogenicity of Ty21a is age dependent.
Murphy
J R
JR
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.
Grez
L
L
Schlesinger
L
L
Ferreccio
C
C
Baqar
S
S
Muñoz
C
C
Wasserman
S S
SS
Losonsky
G
G
Olson
J G
JG
Levine
M M
MM
D000284:Administration, Oral; D000367:Age Factors; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D000942:Antigens, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology* / Q000592:standards; D006801:Humans; D007114:Immunization; D066298:In Vitro Techniques; D007223:Infant; D008213:Lymphocyte Activation; D012485:Salmonella typhi / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology / Q000592:standards
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated